HLN Overview

Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.

Wall Street analysts forecast HLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HLN is13.44 USD with a low forecast of 13.44 USD and a high forecast of 13.44 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Haleon PLC revenue for the last quarter amounts to 2.63B USD, decreased -5.33

Haleon PLC. EPS for the last quarter amounts to USD, decreased -100.00

Haleon PLC (HLN) has 24622 emplpoyees as of May 10 2026.

Today HLN has the market capitalization of 40.43B USD.